Petr Mukenšnábl
- Dermatology top 0.5%
- Surgery top 5%
- Oncology top 5%
- Pathology and Forensic Medicine top 5%
- Rheumatology top 2%
- Co-authors
- Dmitry V. KazakovMichal MichalMichal ZámečníkTomáš VaněčekRadek ŠímaHeinz KutznerL BoudováDominic V. Spagnolo
- Topics
- Cancer and Skin Lesions (29 papers)Sarcoma Diagnosis and Treatment (17 papers)Soft tissue tumor case studies (15 papers)
In The Last Decade
Petr Mukenšnábl
109 papers receiving 1.9k citations
Peers
Comparison fields: 5 of 77
- Dermatology 773
- Surgery 681
- Oncology 623
- Pathology and Forensic Medicine 446
- Rheumatology 439
Countries citing papers authored by Petr Mukenšnábl
This map shows the geographic impact of Petr Mukenšnábl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petr Mukenšnábl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petr Mukenšnábl more than expected).
Fields of papers citing papers by Petr Mukenšnábl
This network shows the impact of papers produced by Petr Mukenšnábl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petr Mukenšnábl. The network helps show where Petr Mukenšnábl may publish in the future.
Co-authorship network of co-authors of Petr Mukenšnábl
This figure shows the co-authorship network connecting the top 25 collaborators of Petr Mukenšnábl. A scholar is included among the top collaborators of Petr Mukenšnábl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petr Mukenšnábl. Petr Mukenšnábl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 15 | |
| 2 | [Where does Ewing sarcoma end and begin - two cases of unusual bone tumors with t(20;22)(EWSR1-NFATc2) alteration]. | 13 |
| 3 | 39 | |
| 4 | 39 | |
| 5 | 89 | |
| 6 | Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. | 33 |
| 7 | 12 | |
| 8 | 15 | |
| 9 | 17 | |
| 10 | 28 | |
| 11 | 5 | |
| 12 | 11 | |
| 13 | 12 | |
| 14 | 70 | |
| 15 | 2 | |
| 16 | 13 | |
| 17 | 24 | |
| 18 | 53 | |
| 19 | 26 | |
| 20 | 40 |
About Petr Mukenšnábl
Petr Mukenšnábl is a scholar working on Dermatology, Rheumatology and Pathology and Forensic Medicine, having authored 114 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cancer and Skin Lesions (29 papers), Sarcoma Diagnosis and Treatment (17 papers) and Soft tissue tumor case studies (15 papers). The work is most often cited by research in Dermatology (773 citations), Rheumatology (439 citations) and Gastroenterology (150 citations). Petr Mukenšnábl has collaborated with scholars based in Czechia, Germany and Australia. Frequent co-authors include Dmitry V. Kazakov, Michal Michal, Michal Zámečník, Tomáš Vaněček, Radek Šíma, Michal Michal, Heinz Kutzner, L Boudová, Dominic V. Spagnolo and Michal Michal. Their work appears in journals such as Circulation, The American Journal of Surgical Pathology and Journal of the American Academy of Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.